Sihuan Pharmaceutical : VOLUNTARY ANNOUNCEMENT SIHUAN PHARMACEUTICAL OBTAINED DRUG REGISTRATION APPROVAL IN RELATION TO RIVAROXABAN TABLETS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sihuan Pharmaceutical Holdings Group Ltd.

̬ᐑᔼᖹછٰණྠϞࠢʮ̡

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

SIHUAN PHARMACEUTICAL OBTAINED DRUG

REGISTRATION APPROVAL IN RELATION

TO RIVAROXABAN TABLETS

The board of directors (the "Board") of Sihuan Pharmaceutical Holdings Group Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that approval of drug registration has been obtained from the National Medical Products Administration of the People's Republic of China ("China") on 25 March 2021 in relation to the Rivaroxaban tablets (10mg and 15mg) developed by the Group, approving the manufacture of the drug, which is deemed to have passed the quality and efficacy consistency evaluation.

Rivaroxaban tablets are a type of Category B drug under the National Reimbursement Drug List, and is a factor Xa inhibitor. It is a new type of oral anticoagulant with the widest range of safe medication experience subjects. Compared to its counterpart Warfarin, Rivaroxaban has a rapid onset of action, a lower risk of intracranial bleeding and does not require routine monitoring of coagulation function during treatment, making it more convenient for patient to use over the long term.

According to the data from Menet, among the Top 10 antithrombotic products in China's public medical hospitals and institutions, 7 products had sales of over RMB1 billion in 2019, with Rivaroxaban tablets ranking second with sales of approximately RMB2.506 billion. Compared to the top ranking product, clopidogrel bisulfate tablets, with sales of approximately RMB11.572 billion, it is expected that there is still significant room for growth in the market for Rivaroxaban tablets.

The approval of drug registration and deemed passing of the consistency evaluation in relation to the Rivaroxaban tablets (10mg and 15mg) developed by the Group will further benefit the majorityof patients. At the same time, with the Group's advantage of owning the active pharmaceutical ingredient (API) for this drug, it is expected to allow for cost reductions in future manufacturing, which will be beneficial to its future market sales and market competition, as well as having positive impact on the operation results of the Group.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board

Sihuan Pharmaceutical Holdings Group Ltd.

Dr. Che Fengsheng

Chairman and Executive Director

Hong Kong, 25 March 2021

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Kim Jin Ha; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.